Key facts
- This page summarizes John Johnson's Form 4 filing for Axogen, Inc. (AXGN).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2025, 17:19.
John Johnson - 08 Dec 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Director
- Issuer ticker
- AXGN
- Reported as of
- 08 Dec 2025
- Net transaction value
- -$1,261,646
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2025, 17:19:01 UTC
- Prior SEC filing
- 15 Aug 2025
- Next SEC filing
- 19 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /S/ Marc Began, as attorney-in-fact for John Johnson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Johnson filed Form 4 for Axogen, Inc. (AXGN) on 10 Dec 2025.
Change
- Previous filing in this sequence was filed on 15 Aug 2025.
- Current net transaction value: -$1,261,646.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001410781
Primary reporting owner
JOHNSON JOHN
- Relationship
- Director
- Address
- C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA
- Signature
- /S/ Marc Began, as attorney-in-fact for John Johnson
- Signature date
- 10 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXGN
transaction
Common Stock
Sale
- Transaction value
- $368,931
- Shares
- -11,802
- Change %
- -47%
- Price
- $31.26
- Shares after
- 13,141
- Date
- 08 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $74,913
- Shares
- +11,891
- Change %
- +90%
- Price
- $6.30
- Shares after
- 25,032
- Date
- 08 Dec 2025
- Ownership
- Direct
AXGN
transaction
Common Stock
Sale
- Transaction value
- $371,273
- Shares
- -11,891
- Change %
- -48%
- Price
- $31.22
- Shares after
- 13,141
- Date
- 08 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $53,834
- Shares
- +8,545
- Change %
- +65%
- Price
- $6.30
- Shares after
- 21,686
- Date
- 09 Dec 2025
- Ownership
- Direct
AXGN
transaction
Common Stock
Sale
- Transaction value
- $256,196
- Shares
- -8,545
- Change %
- -39%
- Price
- $29.98
- Shares after
- 13,141
- Date
- 09 Dec 2025
- Ownership
- Direct
- Footnotes
- F2
AXGN
transaction
Common Stock
Sale
- Transaction value
- $393,993
- Shares
- -13,141
- Change %
- -100%
- Price
- $29.98
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Stock Option (right to purchase)
Options Exercise
- Transaction value
- $0
- Shares
- -11,891
- Change %
- -58%
- Price
- $0.000000
- Shares after
- 8,545
- Date
- 08 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,891
- Exercise price
- $6.30
- Footnotes
- F4
AXGN
transaction
Derivative
Stock Option (right to purchase)
Options Exercise
- Transaction value
- $0
- Shares
- -8,545
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 09 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,545
- Exercise price
- $6.30
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F2
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F3
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F4
Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date.